Eli Lilly

Total: $238.9 million

Top 2 drugs
Cialis: $88.9 million
Cymbalta (pain): $63.3 million; Cymbalta (depression): $34.9 million
Watch the Cymbalta TV commercial here >>

Eli Lilly ($LLY) has been sucking what it can out of Cymbalta while it can. The drug goes off patent at the end of the year, and the expected loss of revenues has wreaked havoc on the company. After letting 40% of its U.S. sales force go, Lilly told everyone else it would freeze salaries and reduce bonuses paid in 2015 to save $400 million through 2016. Lilly actually reported a 3% rise in worldwide revenues to $11.53 billion in the first half of the year, primarily due to--you guessed it--Cymbalta and Cialis, the two drugs it was pushing hard to consumers.

Eli Lilly
Read more on

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.